Displaying drugs 7401 - 7425 of 13634 in total
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.
Investigational
Matched Description: … in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. ... Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use …
Sibrotuzumab
Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Investigational
Matched Description: … Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). …
SLV319
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … It is developed for the treatment of obesity and other metabolic disorders. ... SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
Tolciclate
Experimental
Matched Categories: … Antifungals for Topical Use ... Antifungals for Dermatological Use …
Clometocillin
Experimental
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Sulfametrole
Experimental
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
beta-D-glucuronic acid
Experimental
R450
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Investigational
Matched Description: … R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. ... It is being considered for treatment of stress-related urinary incontinence. ... Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with …
COVID19 s-vax loaded autologous dendritic cell vaccine
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.
Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. ... Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the ... Dendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to …
Bupranolol
Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Experimental
Matched Description: … Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. …
ICG-001
Investigational
Indenolol
Indenolol is a drug of the beta-adrenergic blocker class.
Withdrawn
Matched Description: … Indenolol is a drug of the beta-adrenergic blocker class. …
Peptide YY (3-36)
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity ... It reduces appetite and increases satiety in obese patients. …
XTL-6865
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Investigational
Matched Description: … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment ... XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis …
Teneligliptin
Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.
Investigational
Matched Description: … Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus. …
Matched Categories: … Drugs Used in Diabetes …
Matched Categories: … Drugs Used in Diabetes …
Scriptaid
Scriptaid is a histone deacetylase (HDAC) inhibitor researched for its anti-tumor properties.
Investigational
Matched Description: … Scriptaid is a histone deacetylase (HDAC) inhibitor researched for its anti-tumor properties. …
Cintredekin besudotox
Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor resection. Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, Pseudomonas...
Investigational
Matched Description: … positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating ... Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin ... Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by …
V1003
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
Matched Description: … pain in hospital and home settings. ... Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a ... V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative …
BMS-813160
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
Investigational
Matched Iupac: … N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-({7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl}amino)-2 …
Matched Description: … BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine ... and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC …
Matched Description: … BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine ... and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC …
DDP733
DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in...
Investigational
Matched Description: … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel ... Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal ( ... It is a partial agonist of the serotonin type 3 receptor (5-HT3). …
5-hydroxyvaleric acid
Experimental
4-(Dimethylamino)benzoic acid
Experimental
Muplestim
Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia).
Investigational
Matched Description: … Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate ... the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in …
Epafipase
Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis).
Investigational
Matched Description: … Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis). ... Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human …
Displaying drugs 7401 - 7425 of 13634 in total